Progesterone Receptor Negative Recruiting Phase 1 / 2 Trials for Binimetinib (DB11967)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03106415Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast CancerTreatment